Click on a filter below to refine your search. Remove a filter to broaden your search.
Older age was associated with lower odds of short length of stay in those dually eligible for Medicare and Medicaid.
$2.0 to $5.1 billion would include lecanemab and ancillary costs; estimated annual per-patient coinsurance could reach $6,636